Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study

IF 7.4 2区医学 Q1 CLINICAL NEUROLOGY

CNS drugs Pub Date : 2024-01-25 DOI:10.1007/s40263-024-01064-5

{"title":"Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study","authors":"","doi":"10.1007/s40263-024-01064-5","DOIUrl":null,"url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Background and Objective</h3> <p>Pregabalin is steadily gaining popularity worldwide, with epidemiological studies indicating an increase in labeled, off-labeled, and recreational uses. In Israel, pregabalin prescriptions are not regulated by the controlled substances legislations, prompting a need to examine its usage trends for potential policy adjustments. The objective of this study was to assess trends in pregabalin prescribing during a 10-year period, to characterize demographic and clinical characteristics of individuals prescribed pregabalin, and to identify risk factors associated with high-intensity pregabalin use.</p> </span> <span> <h3>Methods</h3> <p>This retrospective, longitudinal study examined trends in pregabalin prescribing from 2010 to 2019 based on data extracted from the Clalit Health Services (CHS) electronic database. Annual pregabalin prescribing rate was calculated individually for each reporting year. A univariable analysis was conducted to compare the demographic and clinical characteristics of pregabalin users in 2019 with those in 2010. Multivariable regression analysis was performed to assess dose-related patterns by specific demographic and clinical characteristics.</p> </span> <span> <h3>Results</h3> <p>Pregabalin prescription rate more than doubled over 10 years [odds ratio (OR) 2.3, <em>p</em> = 0.001], reaching 7.2 [95% confidence interval (CI) 7.18–7.28] prescriptions per 100 CHS members in 2019. The highest prescription rates were observed among the elderly population (13.2 and 24.1 prescriptions per 100 CHS members for those aged 55–74 and over 75 years old, respectively). Same-year administration of pregabalin with opioids, benzodiazepines, and Z-drugs was common; however, the percentage of patients using these drugs together declined in 2019 compared with 2010 (<em>p</em> < 0.001). Males, patients with low socioeconomic status, patients aged 35–54 years, and those who consumed opioids, benzodiazepines, and Z-drugs received higher pregabalin doses.</p> </span> <span> <h3>Conclusion</h3> <p>Pregabalin use has increased significantly in the Israeli adult-based CHS population, consistent with worldwide data. A growing use over time may indicate overprescription. More studies are needed on misuse patterns to identify populations most susceptible to high-dose and high-intensity pregabalin use.</p> </span>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":"31 1","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40263-024-01064-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Objective

Pregabalin is steadily gaining popularity worldwide, with epidemiological studies indicating an increase in labeled, off-labeled, and recreational uses. In Israel, pregabalin prescriptions are not regulated by the controlled substances legislations, prompting a need to examine its usage trends for potential policy adjustments. The objective of this study was to assess trends in pregabalin prescribing during a 10-year period, to characterize demographic and clinical characteristics of individuals prescribed pregabalin, and to identify risk factors associated with high-intensity pregabalin use.

Methods

This retrospective, longitudinal study examined trends in pregabalin prescribing from 2010 to 2019 based on data extracted from the Clalit Health Services (CHS) electronic database. Annual pregabalin prescribing rate was calculated individually for each reporting year. A univariable analysis was conducted to compare the demographic and clinical characteristics of pregabalin users in 2019 with those in 2010. Multivariable regression analysis was performed to assess dose-related patterns by specific demographic and clinical characteristics.

Results

Pregabalin prescription rate more than doubled over 10 years [odds ratio (OR) 2.3, p = 0.001], reaching 7.2 [95% confidence interval (CI) 7.18–7.28] prescriptions per 100 CHS members in 2019. The highest prescription rates were observed among the elderly population (13.2 and 24.1 prescriptions per 100 CHS members for those aged 55–74 and over 75 years old, respectively). Same-year administration of pregabalin with opioids, benzodiazepines, and Z-drugs was common; however, the percentage of patients using these drugs together declined in 2019 compared with 2010 (p < 0.001). Males, patients with low socioeconomic status, patients aged 35–54 years, and those who consumed opioids, benzodiazepines, and Z-drugs received higher pregabalin doses.

Conclusion

Pregabalin use has increased significantly in the Israeli adult-based CHS population, consistent with worldwide data. A growing use over time may indicate overprescription. More studies are needed on misuse patterns to identify populations most susceptible to high-dose and high-intensity pregabalin use.

查看原文本刊更多论文

普瑞巴林在成年人群中的使用趋势和处方模式：一项为期 10 年的药物流行病学研究

摘要背景和目的普瑞巴林在全球范围内正逐渐受到欢迎，流行病学研究表明其标签使用、非标签使用和娱乐性使用都在增加。在以色列，普瑞巴林的处方不受管制药物立法的监管，因此有必要对其使用趋势进行研究，以便进行潜在的政策调整。本研究的目的是评估 10 年间普瑞巴林处方的趋势，描述普瑞巴林处方者的人口和临床特征，并确定与高强度使用普瑞巴林相关的风险因素。方法这项回顾性纵向研究根据从 Clalit Health Services (CHS) 电子数据库中提取的数据，研究了 2010 年至 2019 年普瑞巴林处方的趋势。对每个报告年份的普瑞巴林年处方率进行了单独计算。通过单变量分析，比较了 2019 年与 2010 年普瑞巴林使用者的人口统计学特征和临床特征。进行了多变量回归分析，以评估与特定人口统计学和临床特征相关的剂量模式。结果普瑞巴林处方率在 10 年内翻了一番多[比值比 (OR) 2.3，p = 0.001]，2019 年达到每 100 名 CHS 会员 7.2 [95% 置信区间 (CI) 7.18-7.28]个处方。老年人口中的处方率最高（55-74 岁和 75 岁以上人群的处方率分别为 13.2 和 24.1/100）。普瑞巴林与阿片类药物、苯二氮卓类药物和 Z 类药物同年用药的情况很普遍；然而，与 2010 年相比，2019 年同时使用这些药物的患者比例有所下降（p <0.001）。男性、社会经济地位较低的患者、35-54 岁的患者以及服用阿片类药物、苯二氮卓类药物和 Z 类药物的患者服用普瑞巴林的剂量较高。结论普瑞巴林在以色列成人 CHS 患者中的使用量显著增加，这与全球数据一致。随着时间的推移，普瑞巴林的使用量不断增加，这可能表明处方过量。需要对滥用模式进行更多的研究，以确定最容易高剂量和高强度使用普瑞巴林的人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS drugs 医学-精神病学

CiteScore

12.00

自引率

3.30%

发文量

审稿时长

6-12 weeks

期刊介绍： CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes: - Overviews of contentious or emerging issues. - Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses. - Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. - Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry. - Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.